Dr. Graff on the KEYNOTE-641 Trial in mCRPC

Julie N. Graff, MD
Published: Monday, Mar 23, 2020



Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

At the 2020 Genitourinary Cancers Symposium, data from cohorts 4 and 5 of the phase II KEYNOTE-199 trial demonstrated that the addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) resulted in moderate activity in patients with chemotherapy-naïve mCRPC who progressed on enzalutamide.

Accordingly, Merck has launched the phase III KEYNOTE-641 trial, in which patients with mCRPC will be randomized to receive either enzalutamide plus placebo or enzalutamide plus pembrolizumab to determine whether the addition of pembrolizumab extends overall survival, concludes Graff.
SELECTED
LANGUAGE


Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

At the 2020 Genitourinary Cancers Symposium, data from cohorts 4 and 5 of the phase II KEYNOTE-199 trial demonstrated that the addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) resulted in moderate activity in patients with chemotherapy-naïve mCRPC who progressed on enzalutamide.

Accordingly, Merck has launched the phase III KEYNOTE-641 trial, in which patients with mCRPC will be randomized to receive either enzalutamide plus placebo or enzalutamide plus pembrolizumab to determine whether the addition of pembrolizumab extends overall survival, concludes Graff.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x